BioCentury
ARTICLE | Company News

Alpine finds public path through Nivalis

April 18, 2017 11:24 PM UTC

Immunology company Alpine Immune Sciences Inc. (Seattle, Wash.) and cystic fibrosis play Nivalis Therapeutics Inc. (NASDAQ:NVLS) said they will merge in an all-stock transaction. Upon the deal's close, expected in 3Q17, the combined company will retain Alpine's name and trade on NASDAQ under a new, as-yet-undetermined ticker.

Alpine CEO Mitchell Gold will lead the combined company. Gold, who was CEO of Dendreon Corp., told BioCentury that Alpine pursued the deal to gain access to public capital, and will not prioritize development of Nivalis' candidates...